Analogs of Luteinizing Hormone-Releasing Hormone (lhrh) in Cancer

Handbook of Biologically Active Peptides

Volumn , Issue , 2006, Pages 421-427

  Schally, Andrew V ^a   Engel, Jorg ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882925846     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369442-3/50063-5     Document Type: Chapter

References (50)

1. Bajo AM, Schally AV, Halmos G, Nagy A Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-esistant MX-1 human breast cancers. Clin Cancer Res 2003, 9:3742-3748.
2. Bajusz S, Csernus VJ, Janaky T, Bokser L, Fekete M, Schally AV new antagonists of LHRH-II. Inhibition and potentation of LHRH by closely related analogs. Int J Peptide Prot Res 1988, 32:425-435.
3. Blamey RW, Jonat W, Kaufmann M, Bianco AR, Namer M Goserelin depot in the treamtent of premenopausal advanced breast cancer. Eur J Cancer 1992, 28:810-814.
4. Chen A, Kaganovsky E, Rahimipour S, Ben-Aroya N, Okon E, Koch Y Two forms of gonadotropin-releasing hormone (GnRH) are expressed in human breat tissue and overexpressed in breast cancer: A putative mechanism for the antiproliferative effect of GnRH by down-regulation of acidic ribosomal phosphoproteins P1 and P2. Cancer Res 2002, 62:1036-1044.
5. D'Amico AV Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer. Urology 2002, 60:32-37.
6. Dondi D, Limonta P, Moretti RM, Marrelli Montaganani M, Garattini E, Motta M Antiproliferative effects, of luteinizing hormone-releasing hormone (LHRH) agonist on human androgen-independent prostate cancer cell line DU 145: Evidence for an autocrine-inhibitory LHRH loop. Cancer Res 1994, 54:4091-4095.
7. Eidne KA, Flanagan CA, Millar RP Gonadotropin-releasing hormone binding sites in human breast carcinoma. Science 1985, 229:989-991.
8. Emons G, Müller V, Ortmann O, Schulz KD Effects of LHRH-analogs on mitogenic signal transduction in cancer cells. J Steroid Biochem Mol Biol 1998, 65:199-206.
9. Emons G, Ortmann O, Schulz KD, Shcally AV Growth-inhibitory actions of analogs of luteinizing hromone releasing hormone on tumor cells. Trends Endocrinol Metab 1997, 8:355-362.
10. Emons G, Schally AV The use of luteinizing hormone releasing hormone agonists and antagonists in gynecological cancers. Reproduction 1994, 9:1364-1379.
11. Engel JB, Keller G, Schally AV, Nagy A, Chism DD, Halmos G Effective treatment of experimental human endometrial cancers with targeted cytotoxic LHRH-analogs AN-152 and AN-207. Fertil Steril 2005, 83:1125-1133.
12. Fekete M, Wittliff JL, Schally AV Characteristics and distribution of receptors for [d-Trp6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Anal 1989, 3:137-147.
13. Gallagher CJ, Oliver RTD, Oram DH, Fowler CG, Blake PR, Mantell BS, et al. A new treatment for endometrial cancer with gonadotropin-releasing hormone analogue. Br J Obstet Gynaecol 1991, 98:1037-1041.
14. Gonzalez-Barcena D, Vadillo-Buenfil M, Cortez-Morales A, Fuentes-Garcia M, Cardenas-Cornjejo I, Comaru-Schally AM, et al. Luteinizing hormone-releasing hormone antagonist SB-75 (Cetrorelix) as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord. Urology 1995, 45:275-281.
15. Gonzalez-Barcena D, Vadillo-Buenfil M, Gomez-Orta F, Fuentes Garcia M, Cardenas-Carnejo I, Graef-Sanchez A, et al. Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benig prostatic hyperplasia and prostatic cancer. Prostate 1994, 24:84-92.
16. Gründker C, Gunthert AR, Millar RP, Emons G Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. J Clin Endocrinol Metab 2002, 87:1427-1430.
17. Halmos G, Arencibia JM, Schally AV, Davis R, Bostwick DG High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. J Urol 2000, 163:623-629.
18. Horvath JE, Bajo AM, Schally AV, Kovacs M, Herbert F, Groot K Effects of long-term treatment with the luteinizing hormonereleasing hormone (LHRH) agonist Decapeptyl and the LHRH antagonist Cetrorelix on the levels of pituitary LHRH receptors and their mRNA expression in rats. Proc Natl Acad Sci 2002, 99:15048-15053.
19. Jiang G, Miller C, Koerberg SC, Porter J, Craig AG, Bhattacharjee S, et al. Betidamino acid scan of the GnRH antagonist Acyline. J Med Chem 1997, 40:3739-3749.
20. Jungwirth A, Schally AV, Halmos G, Groot K, Szepeshazi K, Pinski J, et al. Inhibition of growth of CAKI-I human renal adenocarcinoma in vivo by LH-RH antagonist Cetrorelix, somatostatin analog RC-160 and bombesin antagonist RC-3940-II. Cancer 1998, 82:909-917.
21. Kahan Z, Nagy A, Schally AV, Halmos G, Arencibia JM, Groot K Complete regression of MX-I human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207. Cancer 1999, 85:2608-2615.
22. Karten MJ, Rivier JE Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agaonists and antagonists: Rationale and perspective. Endocr Rev 1986, 7:44-66.
23. Kaufmann M, Jonat W, Blamey R, Cuzick J, Namer M, Fogelman I, et al. Zoladex Early Breast Cancer Research Association (ZEBRA) Trialists' Group. Survival analyses from the ZEBRA study. Goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer 2003, 39:1711-1717.
24. Keller G, Engel JB, Schally AV, Gaiser T, Nagy A, Baker B, et al. Human malignant melanomas expres receptors for luteinizing hormone releasing hormone (LHRH) allowing experimental targeted therapy with cytotoxic LHRH analogue. Cancer Res 2005, In print.
25. Keller G, Schally AV, Gaiser T, Nagy A, Baker B, Halmos G, et al. Receptors for luteinizing hormone releasing hormone (LHRH) expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic LHRH analogues. Clinical Cancer Research 2005, In print.
26. Keller G, Schally AV, Gaiser T, Nagy A, Baker B, Halmos G, et al. Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207. Eur J Cancer 2005, In Print.
27. Klijn JG, Beex LV, Mauriac L, van Zijl JA, Veyret C, Wildiers J, et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast, cancer: A randomized study. J Natl Cancer Inst. 2000, 92:903-911.
28. Letsch M, Schally AV, Szepeshazi K, Halmos G, Nagy A Preclinical evlauation of targeted cytotoxic luteinizing hormonereleasing hormone analog AN-152 in androgen sensitive and insensitive prostate cancers. Clin Cancer Res 2003, 9:4505-4513.
29. Matsuo H, Arimura A, Schally AV Synthesis of the porcine LH- and FSH-releasing hormone by the solid phase method. Biochem Biophys Res Commun 1971, 45:822-827.
30. Matsuo H, Baba Y, Nair RMG, Arimura A, Schally AV Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. Biochem Biophys Res Commun 1971, 43:1334-1339.
31. Millar R GnRH II and type II GnRH receptors. Trends Endocrinol Metab 2003, 14:35-43.
32. Miyazaki M, Nagy A, Schally AV, Lamharzi N, Halmos G, Szepeshazi K, et al. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone. J Natl Cancer Inst 1997, 89:1803-1809.
33. Molineaux CJ, Sluss PM, Bree MP, Gefter ML, Sullivan LM, Garnick MB Suppression of plasma gonadotropins by Abarelix: A potent new LHRH antagonist. Mol Urol 1998, 2:265-268.
34. Moretti RM, Montagnani Marelli M, Van Groeninghen JC, Limonta P Locally expressed LHRH receptors mediate the oncostatic and antimetastatic activity of LHRH agonists on melanoma cells. J Clin Endocrinol Metab 2002, 87:3791-3797.
35. Nagy A, Schally AV, Armatis P, Szepeshazi K, Halmos G, Kovács M, et al. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc Natl Acad Sci USA 1996, 93:7269-7273.
36. Plonowski A, Schally AV, Nagy A, Groot K, Krupa M, Navone NM, Logothesis C Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207. Cancer Letters 2002, 176:57-63.
37. Redding TW, Schally AV Inhibition of prostate tumor growth in two rat models by chronic administration of d-Trp6-LH-RH. Proc Natl Acad Sci USA 1981, 78:6509-6512.
38. Redding TW, Schally AV, Radulovic S, Milovanovic S, Szepeshazi K, Isaacs JT Sustained-release formulations of LH-RH antagonist SB-75 inhibit proliferation and enhance the apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice. Cancer Res 1992, 52:2538-2544.
39. Reissmann T, Engel J, Kutscher B, Bernd M, Hilgard P, Peukert M, et al. Cetrorelix. Drugs Future 1994, 19:228-237.
40. Schally AV Luteinizing hormone releasing-hormone analogues: Their impact on thecontrol of tumorigenesis. Peptides 1999, 20:1247-1262.
41. Schally AV, Arimura A, Baba Y, Nair RMG, Matsuo H, Redding TW, et al. Isolation and properties of the FSH-and LH-releasing hormone. Biochem Biophys Res Commun 1971, 43:393-399.
42. Schally AV, Comaru-Schally AM Hypothalamic and Other Peptide Hormones. Cancer Medicine 2005, In print, B.C. Dekker Publishers, Hamilton, Ontario. 7th Edition. D.W. Kufe, R.E. Pollock, R.R. Weichselbaum, R.C. Bast, T.S. Gansler, J.F. Holland, E. Frei (Eds.).
43. Schally AV, Comaru-Schally AM, Nagy A, Kovacs M, Szepeshazi K, Plonowski A, et al. Hypothalamic hormones and cancer front. Neuroenedocrinol 2001, 22:248-291.
44. Schally AV, Halmos G, Rekasi Z, Arencibia JM The actions of LH-RH agonists, antagonists, and cytotoxic analogs on the LH-RH receptors on the pituitary and tumors. Infertility and Reproductive Medicine Clinics of North America 2001, 12:17-44. P. Devroey (Ed.).
45. Schally AV, Kastin AJ, Arimura A Hypothalamic FSH and LH-regulating hormone, structure, physiology, and clinical studies. Fertil Steril 1971, 22:703-721.
46. Schally AV, Nagy A Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol 1999, 141:1-14.
47. Schally AV, Nagy A New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life Sciences 2003, 72:2305-2320.
48. Schally AV, Nagy A Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab 2004, 15:300-310.
49. Tolis G, Ackman D, Stellos A, Mehta A, Labrie F, Fazekas A, et al. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing agonists. Proc Natl Acad Sci USA 1982, 79:1658-1662.
50. Trachtenberg J, Gittleman M, Steidle C, Barzell W, Friedel W, Pessis D, et al. Abarelix Study Group A phase 3, multicenter, open label, randomized study of, abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol 2002, 167:1670-1674.